



ORIGINAL ARTICLE

OPEN

Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design

Mustafa Al-Karaghoul¹  | Meritxell Ventura-Cots^{2,3} | Yu Jun Wong¹  |
 Joan Genesca^{2,3} | Francisco Bosques⁴ | Robert S. Brown Jr⁵ |
 Philippe Mathurin⁶ | Alexandre Louvet⁶ | Debbie Shawcross⁷ |
 Victor Vargas^{2,3} | Elizabeth C. Verna⁸ | Bernd Schnabl⁹ | Joan Caballeria³ |
 Vijay J. Shah¹⁰ | Patrick S. Kamath¹⁰ | Michael R. Lucey¹¹ |
 Guadalupe Garcia-Tsao^{12,13} | Ramon Bataller^{14,15,16} | Juan G. Abraldes¹ 

¹Division of Gastroenterology (Liver Unit). University of Alberta, Edmonton, Alberta, Canada

²Liver Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain

³Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain

⁴Hospital Universitario Dr Jose E. Gonzalez, Servicio de Gastroenterología, Universidad Autonoma de Nuevo Leon Monterrey, Mexico

⁵Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA

⁶University of Lille, Inserm, CHU Lille, U1286-INFINITI-Institute for Translational Research in Inflammation, Lille, France

⁷Department of Inflammation Biology, Institute of Liver Studies, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College, London, UK

⁸Division of Digestive and Liver Diseases, Department of Medicine, Columbia College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, USA

⁹Medicine, University of California San Diego, La Jolla, California, USA

¹⁰Mayo Clinic and Mayo Medical School, Rochester, Minnesota, USA

¹¹Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

¹²Section of Digestive Diseases, Yale University, New Haven, Connecticut, USA

¹³Department of Veterans Affairs, Connecticut Healthcare, New Haven, Connecticut, USA

¹⁴Division of Gastroenterology, Hepatology and Nutrition, Center for Liver Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

¹⁵Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

¹⁶Liver Unit, Hospital Clínic, Barcelona, Spain

Abbreviations: AH, alcohol-associated hepatitis; GAHS, Glasgow alcoholic hepatitis score; InTeam, Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis; MELD, Model for End-Stage Liver Disease; NIAAA, National Institute on Alcohol Abuse and Alcoholism; NIH, National Institutes of Health; RCT, randomized controlled trial.

Mustafa Al-Karaghoul and Meritxell Ventura-Cots share the first authorship.

Ramon Bataller and Juan G. Abraldes share senior authorship.

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.hepcommjournal.com.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.

Correspondence

Juan Gonzalez Abraldes, Division of Gastroenterology, University of Alberta, 1-38 Zeidler Leducor Centre, 8540 112 St NW, Edmonton, AB T6G 2X8, Canada.
Email: juan.g.abraldes@ualberta.ca

Abstract

Background: Alcohol-associated hepatitis (AH) is associated with significant mortality. Model for End-Stage Liver Disease (MELD) score is used to predict short-term mortality and aid in treatment decisions. MELD is frequently updated in the course of AH. However, once the most updated MELD is known, it is uncertain if previous ones still have prognostic value, which might be relevant for transplant allocation and trial design. We aimed to investigate the predictive performance of updated MELDs in a prospectively collected cohort of patients with AH by the InTeam consortium.

Methods: Three hundred seven patients (with 859 MELD values within 60 d of admission) fulfilled the inclusion criteria. The main endpoint was time to death or transplant up to 90 days. We used a joint model approach to assess the predictive value of updated MELDs.

Results: Updated MELD measurements had a strong prognostic value for death/transplant (HR: 1.20, 95% CI: 1.14–1.27) ($p < 0.0001$). Previous MELD values did not add predictive value to the most current MELD. We also showed that MELD at day 28 (MELD28) had a significant predictive value for subsequent mortality/transplant in a landmark analysis (HR: 1.18, 95% CI: 1.12–1.23). We show that the use of an ordinal scale including death, transplant, and MELD28 as a trial outcome could substantially reduce the sample size required to demonstrate short-term benefit of an intervention.

Conclusion: We show that updated MELDs during the trajectory of AH predict subsequent mortality or the need for transplant. MELD28 inclusion in an ordinal outcome (together with death or transplant) could increase the efficiency of randomized controlled trials.

INTRODUCTION

Alcohol-associated hepatitis (AH) is associated with significant morbidity and mortality.^[1,2] Several prognostic risk scores have been developed to assess disease severity and mortality, and determine candidates who might benefit from pharmacological intervention, such as corticosteroids.^[3–8] Static models, including Maddrey's modified discriminant function, the ABIC (age, bilirubin, international normalized ratio, and creatinine score) score, the Glasgow alcoholic hepatitis score (GAHS), and the Model for End-Stage Liver Disease (MELD), are assessed at baseline for predicting short-term mortality and selecting candidates for treatment.^[3–6] In contrast, dynamic models may afford more subtle differentiation in the predicted outcome of AH. We have shown previously that serial estimation of serum bilirubin stratifies patients and identify those likely to recover, in whom corticosteroids confer no benefit.^[9] Following treatment with corticosteroids, the dynamic Lille model

calculated at days 4 or 7 is used to evaluate treatment response.^[10,11] Furthermore, a model using both baseline MELD and 7-day Lille score proved to be superior to models using only baseline data to predict prognosis in AH.^[11]

MELD score is increasingly used to select patients for treatment, and current guidelines suggest a threshold of >20 points to start steroids.^[12] Indeed, recent observational data suggest that corticosteroids reduce short-term mortality in patients with MELD scores ranging from 21 to 51, with the greatest impact observed in individuals with MELD scores between 25 and 39 while offering no significant mortality benefit with MELD values below 20.^[2]

In day-to-day practice, MELD is measured repeatedly during the first few weeks after the onset of an AH episode to reassess the prognosis of the patient and to make therapeutic decisions regarding liver transplant. However, the value of updated MELD measurements in predicting survival has not been thoroughly assessed. Furthermore, it is unclear if the change in MELD (or rate

of change) captures the risk of death better than the most up-to-date value (or “current” value). Understanding the prognostic value of MELD during the first few weeks of the AH episode could also help optimize the design of randomized controlled trials (RCTs) by using MELD as a surrogate measure of outcome (death/transplant). Indeed, designs focused on short-term (28 d) mortality as a binary primary outcome have shown insufficient power to detect the benefit of pharmacological interventions.^[13–15] In this context, the use of MELD at 28 days (MELD28) in those alive without a transplant could markedly improve the power of such trials.

Therefore, in this study, we aimed at evaluating, in a prospective cohort of patients admitted with AH, (a) the value of updated MELD scores during the first 60 days after presentation to predict mortality up to 90 d, (b) whether the predictive value of a given MELD at any time point during follow-up depends on the previous trajectory of MELD (or, on the contrary, the only predictive MELD is the current MELD), (c) what is the value of MELD28 to predict subsequent mortality, and (d) the impact of using MELD28 as part of an ordinal outcome in the power of randomized trials for AH.

METHODS

Data on 341 patients hospitalized with AH between 2014 and 2018 were collected from the prospective InTEAM central database. InTeam was an NIH-supported consortium of 13 centers across the United States, Canada, Mexico, France, Spain, and the United Kingdom. All centers were tertiary-care liver transplant centers. AH was defined by the InTEAM members according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria, and patients with *probable* or *definite* AH were eligible for inclusion.^[16] The inclusion criteria were as follows: age between 18 and 70, all patients had excessive alcohol use in the 3 months before admission, aspartate aminotransferase > alanine aminotransferase, and total bilirubin > 3 mg/dL. A liver biopsy was performed as per the standard of care in each center. The exclusion criteria were other or multiple etiologies, including autoimmune, viral, HCC, complete PVT, pregnancy or breastfeeding, terminal extrahepatic diseases, and specific treatment for AH (ie, corticosteroids and/or pentoxifylline) 3 or more days before study inclusion. For the purpose of this study, only patients with a minimum follow-up period of 7 days were included. Thus, the final sample size for the present study was 307 patients. Patients were managed according to the standard of care at each center. Previous results from this cohort have been reported.^[17] Severe AH was defined by MELD > 20. MELD score was capped at 40. The endpoint for the present substudy of the InTeam cohort was *time to death or transplant* (up to 90 d).

All research was conducted in accordance with both the Declarations of Helsinki and Istanbul. The InTeam

consortium study (clinical bio-repository) was approved by the institutional review committee of each center and each patient provided informed consent.

Statistical analysis

Analyses were conducted using R statistical software (R Foundation for Statistical Computing) with packages JMbayes2,^[18] survival,^[19] rms,^[20] Hmisc.^[21]

To assess the value of the updated MELD score in the dynamic prediction of mortality/transplant, we used a joint modeling approach with JMbayes2 R package.^[18] This consists of 2 linked submodels, the longitudinal submodel (a linear mixed model) that predicts the “instantaneous” MELD value for every patient during the first 60 days and a Cox proportional hazard model of transplant-free survival. The main difference between this approach and a Cox model introducing MELD as a time-dependent covariate is that the latter uses only the “measured” values of MELD. For example, in a patient who had a MELD of 30 at day 7, and the next measured MELD was at day 28 and had a value of 20, the Cox model with time-dependent MELD would consider that the patient had a constant MELD of 30 between day 7 and day 27, and then abruptly dropped to 20 on day 28. In the joint model, the MELD trajectory is first modeled for every patient with the linear mixed model, and takes into account the irregular time points at which MELD was measured and the censoring of the patients. The joint model includes the subject-specific linear predictors of the mixed-effects models as time-varying covariates in the Cox survival model. Therefore, it uses the modeled MELD, which better represents what happened to MELD between days 7 and 28 in a given patient. The accuracy of the model was assessed using the c-statistic (discrimination) and integrated Brier score (overall performance).^[22]

The joint model also allows testing whether the previous slope of MELD trajectory or the cumulative exposure to MELD adds predictive value to the current MELD (ie, if at a given time point and once the most up-to-date MELD is known, whether previous values added any additional prognostic information).^[23] We additionally tested the potential modifying effect of age, sex, and severity of AH with an interaction test.

Since the 28-day time point has been used as the primary outcome for randomized trials,^[13,24–31] we conducted a landmark analysis as a complementary approach to the joint model, setting time zero of follow-up at day 28. In this analysis, we used a Cox model to assess the predictive value of MELD28 (in those alive, not transplanted, and still at follow-up at 28 d) on the risk of death or transplant up to 90 days from the initial presentation. Since not all patients still at risk (not dying before 28 d and not lost to follow-up) had MELD measured exactly at day 28, we used the predicted MELD28 (using the linear mixed model).

Finally, and based on the distribution of MELD values in those patients alive and not transplanted (and still at follow-up) at day 28, we estimated the sample size for potential randomized trials using either a binary outcome (death/transplant vs alive at 28 d) or an ordinal outcome. This ordinal outcome is based on a scale that has death as the worst outcome, transplant as the next worst, and then the ordered distribution of MELDs. The thresholds to define MELD categories were chosen for illustration purposes. We provide sample sizes for the assumptions of proportional odds^[32] and a power 0.8, using the function *posamsize* in the Hmisc package.^[21] In addition, we provide in the Supplemental Methods, <http://links.lww.com/HC9/A976>, a function to estimate the power based on trial simulations with an ordinal outcome as described.

RESULTS

Baseline characteristics of the cohort

For the present study, 307 patients with AH fulfilled our inclusion criteria. Supplemental Figure S1, <http://links.lww.com/HC9/A976>, shows the disposition of the patients, and Table 1 shows their baseline characteristics. The overall risk of death or transplantation was markedly different between patients with severe (15.7%, 27.2%, and 29.5% at 30, 60, and 90 d) and moderate AH (3.6%,

TABLE 1 Baseline characteristics of the patients in the study cohort

Variable (Units)	Total
Total number of patients (%)	307 (100)
Sex, n (%)	
Female	106 (34.5)
Male	201 (65.5)
Age (y)	49.0 (40.0–57.0)
Albumin (g/dL)	2.5 (2.1–3.0)
Bilirubin (mg/dL)	12.3 (6.3–20.5)
INR (unit)	1.8 (1.5–2.1)
Platelet ($10^9/L$)	125 (79–206)
AST (U/L)	128.0 (96.0–193.0)
ALT (U/L)	45.0 (31.8–66.3)
ALP (U/L)	173.0 (120.8)
GGT (U/L)	555.0 (115.5–669.0)
Creatinine (mg/dL)	0.7 (0.6–1.1)
MELD	23.0 (20.0–27.0)
Severity of AH, n (%)	
Moderate	84 (27.4)
Severe	223 (72.6)

Note: Values of continuous variables represent the median (25–75 percentiles). Abbreviations: AH, alcohol-associated hepatitis; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; INR, international normalized Ratio; MELD, Model for End-Stage Liver Disease.

6.3%, and 6.3%, respectively) (Supplemental Figure S2, <http://links.lww.com/HC9/A976>).

Serial MELD and prognosis (joint model approach)

Figure 1A shows the available MELD data points ($n = 859$) within 60 days of inclusion in the study. To assess the value of serial MELD measurements on prognosis, we constructed a joint model as described in the Methods section. Details of the longitudinal model to predict current MELD are provided in Supplemental Table S1, <http://links.lww.com/HC9/A976>. Figure 1B provides examples of how this model approximates individual MELD trajectories for each patient.

The joint model showed a significant association between the current MELD value and the risk of death/transplant ($p < 0.0001$) with an HR of 1.20 (95% CI: 1.14–1.27). Thus, at any time during the first 60 days of follow-up, a unit difference in MELD was associated with a 20% relative difference in the rate of death/transplant. Figure 2 summarizes graphically the results of the joint model predictions, showing how the probability of death/transplant is updated over time. The performance of the MELD-based joint model at different time points is shown in Supplemental Table S2, <http://links.lww.com/HC9/A976>, showing how the accuracy of prediction increases as MELD values are updated.

We also assessed if once the most updated or current MELD value is known, the previous trajectory of MELD provides prognostic information. As discussed in the Methods section, the joint model allows to introduce different parameterizations, including the slope of the predictor (which reflects previous MELD trajectory) and the total cumulative MELD exposure. Neither the MELD slope ($p = 0.776$) nor the cumulative MELD exposure ($p = 0.538$) significantly added prognostic value to the current MELD value (Supplemental Table S3, <http://links.lww.com/HC9/A976>), indicating that once the current MELD is known, previous MELD values do not add additional predictive information for the risk of death/transplant.

Finally, to understand potential modifiers of the predictive value of MELD, we tested, in the joint model, the interactions of MELD with age, sex, and corticosteroid treatment (Supplemental Table S4, <http://links.lww.com/HC9/A976>). Only age, but not sex or corticosteroids, significantly interacted with MELD.

MELD value at 28 days (MELD28) and prognosis (landmark analysis approach)

To further test the robustness of the joint model predictions, we used a landmark approach to assess




FIGURE 1 (A) Available MELD data points within 60 days of inclusion in the study (n = 859). Clear green points represent values of MELD from patients classified at baseline as moderate AH (MELD ≤ 20 at baseline), while dark green points are from patients classified as severe AH at baseline. (B) Examples of how the longitudinal model fits predicted MELD trajectories in 15 of the patients from the study cohort. Abbreviation: MELD, Model for End-Stage Liver Disease.

the predictive ability of the MELD-28 score for mortality within the 90-day period (62 d after the landmark). Since not all patients had MELD measured on day 28, in those patients who were alive and still on follow-up on day 28, we used the longitudinal model to predict the MELD-28 value. The MELD-28 value was introduced in a Cox model that had day 28 as time zero of follow-up. There were 33 events (4 transplants and 29 deaths) between day 28 and day 90). MELD-28 was strongly predictive of subsequent mortality ($p < 0.0001$) with excellent discrimination and calibration (Supplemental Table S5, <http://links.lww.com/HC9/A976>). The HR for transplant-free survival for every unit of MELD was 1.18 (95% CI: 1.12–1.23). **Figure 3** shows a nomogram with mortality predictions based on MELD-28. To test whether baseline MELD would add prognostic information to MELD-28, we introduced the baseline MELD as a predictor together with 28-day MELD. Baseline MELD did not add predictive value to MELD-28 ($p = 0.716$) (Supplemental Table S6, <http://links.lww.com/HC9/A976>). This is in line with the results obtained with the joint model, showing that once the MELD at a given time point is known, previous MELD scores do not add predictive value.

Severity of AH and MELD prediction

To further assess the impact of AH severity (moderate AH vs. severe AH) on MELD predictions, we conducted 2 analyses. We first showed that the association between MELD across all levels of severity and death/transplant does not significantly depart from linearity (Supplemental Figure S3, <http://links.lww.com/HC9/A976>). Second, the interaction between MELD and the severity of AH on the joint model was tested. We found the interaction was nonsignificant (Supplemental Table S4, <http://links.lww.com/HC9/A976>), suggesting the association between the current MELD and prognosis is not affected by how the patient was classified at admission in terms of the severity of AH.

Implications for trial design and the use of an ordinal outcome to assess efficacy in RCTs

Since MELD28 is strongly predictive of subsequent mortality, it would have the potential to be used as part of an ordinal outcome to assess the efficacy of new treatments for AH. Since current mortality rates of AH are decreasing, it will be difficult to power a study to demonstrate benefit with a binary endpoint death/transplant as the primary outcome. We, therefore, provide an example of the impact of including MELD28 as part of an ordinal scale that would include mortality as the most severe category, transplant as the next

most severe, and the distribution of MELD28 values in those patients still alive and not transplanted at day 28. **Table 2** shows the distribution of this ordinal scale in our cohort, both for the subset of patients with severe AH and moderate AH, and the potential distribution of the patients across the ordinal scale for different effect sizes of a new experimental treatment. In **Table 3**, we show the sample sizes required to demonstrate a benefit in an RCT for severe AH, using a binary endpoint as compared to the use of an outcome based on the ordinal scale. As shown in the table, the needed number of patients would markedly decrease by incorporating the distribution of MELD28 into the outcome. We present similar data for trials for moderate AH in Supplemental Tables S7, <http://links.lww.com/HC9/A976> and S8, <http://links.lww.com/HC9/A976>.

DISCUSSION

In this study, we assessed the value of serial MELD measurements during the first 60 days in patients admitted with AH to predict mortality for up to 90 days. First, we showed that updated MELD scores were strongly associated with the risk of death or transplantation in patients with AH. We showed a significant improvement in the prediction accuracy when the predictions were made closer to the time horizon to evaluate the outcome. This is relevant for patient care because it reflects the current practice in which blood tests are repeated serially in patients with AH both during hospitalization and after discharge.

Second, we showed that adding the previous MELD did not enhance the predictive value of the current MELD. This supports the current general strategy of MELD use in transplant allocation and prioritization (where only the most up-to-date value is used for ranking purposes) and also for patients with AH. We confirmed this concept in 3 ways. The joint model allows testing the effect of the previous slope and the previous cumulative exposure to the variable under assessment. We found that neither the slope nor the previous total MELD exposure added significant predictive value to the current MELD. As a confirmatory approach, we conducted a landmark analysis to test the predictive value of MELD at 28 days, confirming that the MELD28 value is strongly predictive of subsequent mortality. Again, once the MELD28 value is known, the baseline MELD does not add predictive value, confirming the results of the joint model approach.

The strong prognostic value of MELD in the first few weeks of AH suggests that the distribution of MELD values at a given time point during the trajectory of AH (in those patients not dying or not getting a transplant) could be used to enhance the design of RCTs. As we show in **Table 3**, the sample size needed to demonstrate efficacy with a binary endpoint (death or transplant) in the current




FIGURE 2 Dynamic MELD prediction in patients with progressive serial MELD measurement at baseline, day 15, day 30, and day 60. The mortality risk portion of the graph represents the risk of transplant/death with the 95% prediction interval. (A) Example of a patient with decreasing MELD from 40 to 20. (B) Example of a patient with a stable MELD of 30. Abbreviation: MELD, Model for End-Stage Liver Disease.

context of AH trials makes the logistics of these trials difficult. Several fields have incorporated the use of ordinal outcomes as the primary endpoint to demonstrate

efficacy, with recent examples in stroke,^[33] COVID-19,^[34] and pulmonary hypertension.^[35] An ordinal outcome for AH trials could include death as the worst category,




FIGURE 3 Nomogram showing the 60-day and 90-day transplant-free survival probability based on the 28-day MELD score. Abbreviation: MELD, Model for End-Stage Liver Disease.

TABLE 2 Distribution of the patients with severe AH at 28 days according to the ordinal scale in the InTeam cohort, and after applying different effect sizes

Ordinal scale		Distribution of patients according to the ordinal scale at day 28				
		InTeam (%)	Expected distribution in a treatment arm applying different ORs			
			OR: 0.77 (%)	OR: 0.72 (%)	OR: 0.65 (%)	OR: 0.50 (%)
8	Death	12.4	9.8	9.2	8.4	6.6
7	Transplant	1.9	1.6	1.5	1.4	1.1
6	MELD = > 30	7.1	5.9	5.7	5.3	4.3
5	MELD 30–25	13.3	11.7	11.3	10.6	9.0
4	MELD 25–20	16.2	15.4	15.1	14.6	13.1
3	MELD 20–17.5	20.5	21.4	21.5	21.6	21.4
2	MELD 17.5–15	17.6	20.4	21.1	22.2	24.7
1	MELD < 15	11	13.8	14.6	15.9	19.8

Note: The distribution of MELDs applies to those patients alive, not transplanted, and still in follow-up at day 28. Abbreviations: AH, alcohol-associated hepatitis; MELD, Model for End-Stage Liver Disease.

transplant as the second worst, and the distribution of MELDs in those not having death or transplant. For illustration purposes, we chose the distribution across 6 categories of MELD, but MELD-28 could also be used as a continuous variable. The use of such an outcome would substantially increase power and decrease the sample size for a given effect size (Table 3). Since it is highly unlikely that an improvement in creatinine, bilirubin, or international normalized ratio induced by an experimental treatment would be followed by a worsening (or lack of improvement) in patient outcomes, such an ordinal scale would likely have high credibility for regulatory agencies. Indeed, the most up-to-date MELD in a given patient is already used in one of the most critical decisions in hepatology, such as when indicating a transplant and when ranking a given patient

TABLE 3 Potential impact of the use of an ordinal outcome on the sample size in patients with severe AH

Sample size for an RCT in severe AH (assuming a distribution of outcomes at day 28 in the placebo arm as in the InTeam cohort)		
Effect size (OR)	Endpoint at day 28	
	Dichotomous (Death/transplant vs. alive)	Ordinal scale 8 categories (Death, transplant, MELD distribution in those alive)
0.77 ^a	3750	1413
0.72 ^b	2374	895
0.65	1381	520
0.5	533	201

Note: There was a marked decrease in the needed sample size when using an ordinal scale as the primary outcome, as compared to the dichotomous outcome. Sample size calculations were for a proportional odds model with 80% power.

^a0.77: approximate effect size (HR) observed in Louvet et al.^[14]

^bEffect size (unadjusted OR) observed in Thursz et al.^[13]

Abbreviations: AH, alcohol-associated hepatitis; MELD, Model for End-Stage Liver Disease; RCT, randomized controlled trial.

on the waiting list. Furthermore, the trial itself could incorporate analyses to document that the effect on the harder outcomes (death or transplant) is consistent with the effect on the milder outcomes (MELD distribution) by checking the proportional odds assumption.

The additional advantage of an ordinal outcome would be the possibility of testing efficacy at earlier time points. It is well established that in AH, the drivers of short-term and long-term outcomes differ, and hence the therapeutic targets might be different.^[36] Indeed, after a few weeks, the prognosis of AH is mostly dependent on whether the patient continues/resumes using alcohol.^[36,37] In addition, patients with AH are frequently lost to follow-up, which makes it difficult to have complete trial data in long trials. Therefore, trials with a short time horizon to assess an acute intervention early in the trajectory of AH (such as it was done, eg, in the STOPAH trial^[13]) would be an important step forward for drug development.

Finally, an ordinal outcome seems the only feasible option for trials in moderate AH, in which short-term mortality is exceedingly low. An alternative that has been proposed for these trials is the assessment of MELD change. However, change from baseline is difficult to interpret since higher values tend to have higher chances of change, and a similar change might have a very different meaning according to the baseline. In the framework of ordinal outcomes, the baseline MELD can be easily incorporated into the analysis as a covariate, allowing a direct and easy interpretation of the resulting OR as “for patients that were equally sick at baseline what were the chances of an improvement in outcome with the new treatment.”

Our study has several strengths. The information was collected prospectively in 13 centers across 6 different countries, which enhances the study’s external validity and generalizability to diverse populations. Second, our modeling strategy used a single variable (MELD), so there is minimal risk of overfitting in our analysis. Finally, we used complementary approaches to address the study

question (joint model and landmark analysis), showing consistent results. The main limitation of the study is the lack of standardized time points for measuring MELD. This is difficult to fulfill in a cohort of patients with AH. There was indeed a substantial proportion of patients lost to follow-up. Fifteen percent of the patients in the original cohort were lost to follow-up by day 90. Another limitation is that the transplant landscape for AH has substantially changed, especially after 2018.^[38] Still, since the main driver for transplant indication and prioritization is MELD, the impact of an increased rate of transplant on the interpretation of our findings would be low. Finally, we acknowledge that we used MELD in its original iteration in this study. Over time, newer iterations of MELD, designed to improve accuracy and limit unintended bias against women, have been introduced.^[39,40] We suspect that our findings here would be replicated by MELD 3.0, but this would have to be tested.

In conclusion, we show here that updated MELDs during the trajectory of AH are strongly associated with prognosis. This suggests that incorporating MELD scores as part of an ordinal outcome may be a sound approach to improve efficiency in therapeutic trials for AH.

FUNDING INFORMATION

This study was supported by the National Institutes on Alcohol Abuse and Alcoholism (NIAAA U01AA021908). Meritxell Ventura-Cots received financial support from JR19/00015 and PI22/01770. Bernd Schnabl is supported by NIH center P30 DK120515.

CONFLICTS OF INTEREST

Juan G. Abraldes reports consulting for Boehringer Ingelheim, AstraZeneca, Advanz, 89Bio, and Boston Pharmaceuticals. He received research grants from Cook and Gilead paid to the University of Alberta. Bernd Schnabl consults for Amby's Medicines, Ferring Research Institute, Gelesis, HOST Therabiomics, Intercept Pharmaceuticals, Mabwell Therapeutics, Surrozen, Patara Pharmaceuticals, and Takeda. Bernd Schnabl is the founder of Nterica Bio. UC San Diego has filed several patents with Bernd Schnabl as an inventor. Bernd Schnabl's institution, UC San Diego, has received research support from Artizan Biosciences, Axial Biotherapeutics, BiomX, CymaBay Therapeutics, NGM Biopharmaceuticals, Prodigy Biotech, Intercept, Chromologic, and Synlogic Operating Company. Robert S. Brown Jr consults for Abbvie, Gilead, eGenesis, Intercept, and Mallinckrodt. He received grants from Durect. Philippe Mathurin consults for Agomab Therapeutics and Intercept. Debbie Shawcross consults, advises, is on the speakers' bureau, and has received grants from EnteroBiotix. She consults, is on the speakers' bureau, and has received grants from Norgine. She consults and advises Satellite Bio and MRM Health. She consults for Apollo Therapeutics. Victor Vargas advises Ipsen. Elizabeth Verna received grants from Salix. Ramon Bataller consults for GlaxoSmithKline Novo Nordisk, and Boehringer Ingelheim.

He is on the speakers' bureau for Abbvie and Gilead. Juan G. Abraldes consults for 89Bio, Boehringer Ingelheim, AstraZeneca, Advanz, Boston Pharmaceuticals, and Novo Nordisk. He received grants from Cook and Gilead. Joan Genesca consults for Boehringer Ingelheim and is on the speakers' bureau for Echosens. The remaining authors have no conflicts to report.

ETHICS APPROVAL

Each participating center obtained approval from their institutional ethics committee (IRB from the University of Pittsburgh as a coordinator center PRO17040075)

ORCID

Mustafa Al-Karaghoul  <https://orcid.org/0000-0002-0668-6002>

Yu Jun Wong  <https://orcid.org/0000-0002-0727-1183>

Juan Gonzalez Abraldes  <https://orcid.org/0000-0003-3421-937X>

REFERENCES

- Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KVN, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. *Hepatology*. 2005;41:353–8.
- Arab JP, Diaz LA, Baeza N, Idalsoaga F, Fuentes-López E, Arnold J, et al. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. *J Hepatol*. 2021;75:1026–33.
- Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. *J Hepatol*. 2005;42:700–6.
- Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. *Gut*. 2005;54:1174–9.
- Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. *Gastroenterology*. 1978;75:193–9.
- Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. *Am J Gastroenterol*. 2008;103:2747.
- Morales-Arárez D, Ventura Cots M, Altamirano J, Abraldes JG, Cruz-Lemini M, Thursz MR, et al. The MELD score is superior to Maddrey's discriminant function score to predict short-term mortality in alcohol-associated hepatitis: A global study. *Am J Gastroenterol*. 2022;117:301–10.
- Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology*. 2000;31:864–71.
- Parker R, Cabezas J, Altamirano J, Arab JP, Ventura-Cots M, Sinha A, et al. Trajectory of serum bilirubin predicts spontaneous recovery in a real-world cohort of patients with alcoholic hepatitis. *Clin Gastroenterol Hepatol*. 2022;20:e289–97.
- Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology*. 2007;45:1348–54.
- Louvet A, Labreuche J, Artru F, Boursier J, Kim DJ, O'Grady J, et al. Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis. *Gastroenterology*. 2015;149:398–406.e8.

12. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2020;71:306–33.
13. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. *N Engl J Med*. 2015;372:1619–28.
14. Louvet A, Labreuche J, Dao T, Thévenot T, Oberti F, Bureau C, et al. Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: A randomized clinical trial. *JAMA*. 2023;329:1558–66.
15. Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Gorla O, Chatalein D, et al. Glucocorticoids plus *N*-acetylcysteine in severe alcoholic hepatitis. *N Engl J Med*. 2011;365:1781–9.
16. Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the NIAAA Alcoholic Hepatitis Consortia. *Gastroenterology*. 2016;150:785–90.
17. Musto JA, Eickhoff J, Ventura-Cots M, Abraldes JG, Bosques-Padilla F, Verna EC, et al. The level of alcohol consumption in the prior year does not impact clinical outcomes in patients with alcohol-associated hepatitis. *Liver Transpl*. 2021;27:1382–91.
18. Rizopoulos D, Papageorgiou G, Afonso PM. *JMbayes2*: Extended joint models for longitudinal and time-to-event data. March 13, 2023. Accessed May 2, 2023. <https://cran.r-project.org/web/packages/JMbayes2/index.html>
19. Therneau TM, Lumley T (original S > R port and R maintainer until 2009), Elizabeth A, Cynthia C. survival: Survival Analysis. March 12, 2023. Accessed May 2, 2023. <https://cran.r-project.org/web/packages/survival/index.html>
20. Harrell Jr FE. rms: Regression Modeling Strategies. April 9, 2023. Accessed May 2, 2023. <https://cran.r-project.org/web/packages/rms/index.html>
21. Harrell Jr FE, Dupont C (contributed several functions and maintains latex functions). Hmisc: Harrell Miscellaneous. May 8, 2023. Accessed July 27, 2023. <https://cran.r-project.org/web/packages/Hmisc/index.html>
22. Dynamic predictions. Accessed July 26, 2023. https://drizopoulos.github.io/JMbayes2/articles/Dynamic_Predictions.html
23. Univariate and multivariate joint models. Accessed July 26, 2023. <https://drizopoulos.github.io/JMbayes2/articles/JMbayes2.html>
24. Carithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. *Ann Intern Med*. 1989;110:685–90.
25. Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo—A meta-analysis of individual data from controlled trials. *Gastroenterology*. 2018;155:458–468.e8.
26. Higuera-de la Tijera F, Servín-Caamaño AI, Serralde-Zúñiga AE, Cruz-Herrera J, Pérez-Torres E, Abdo-Francis JM, et al. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. *World J Gastroenterol*. 2015;21:4975–85.
27. Hassanein T, McClain CJ, Vatsalya V, Stein LL, Flamm SL, Martin P, et al. Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis. *Am J Gastroenterol*. 2024;119:107–15.
28. Mathurin P, Dufour J-F, Bzowej NH, Shiffman ML, Arterburn S, Nguyen T, et al. Selonsertib in combination with prednisolone for the treatment of severe alcoholic hepatitis: a phase 2 randomized controlled trial. *Hepatology*. 2018;68:8A–9A.
29. Conatus Pharmaceuticals Inc. A placebo-controlled, multicenter, double-blind, randomized trial of IDN-6556 in patients with severe alcoholic hepatitis and contraindications to corticosteroid therapy. *clinicaltrials.gov*. 2016. Accessed July 26, 2023. <https://clinicaltrials.gov/study/NCT01912404>
30. Virginia Commonwealth University. A multicenter randomized, double-blind, placebo-controlled, dosing, safety and efficacy study of IMM 124-E (hyperimmune bovine colostrum) for patients with severe alcoholic hepatitis. *clinicaltrials.gov*. 2020. Accessed July 26, 2023. <https://clinicaltrials.gov/study/NCT01968382>
31. Mitchell M. Novel therapies in moderately severe acute alcoholic hepatitis. *clinicaltrials.gov*. 2022. Accessed July 26, 2023. <https://clinicaltrials.gov/study/NCT01922895>
32. Harrell F. Statistical thinking—Violation of proportional odds is not fatal. September 20, 2020. Accessed July 27, 2023. <https://www.fharrell.com/post/po/>
33. Anderson CS, Robinson T, Lindley RI, Arima H, Lavados PM, Lee TH, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. *N Engl J Med*. 2016;374:2313–23.
34. Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Mentré F, Burdet C, et al. Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. *Lancet Infect Dis*. 2022;22:764–5.
35. Hoepfer MM, Badesch DB, Ardeschir Ghofrani H, Gibbs SR, Gombert-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. *N Engl J Med*. 2023;388:1478–90.
36. Louvet A, Labreuche J, Artru F, Bouthors A, Rolland B, Saffers P, et al. Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study. *Hepatology*. 2017;66:1464.
37. Altamirano J, López-Pelayo H, Michelena J, Jones PD, Ortega L, Ginès P, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival. *Hepatology*. 2017;66:1842.
38. Cotter TG, Sandıkçı B, Paul S, Gampa A, Wang J, Te H, et al. Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency. *Am J Transplant*. 2021;21:1039–55.
39. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. *N Engl J Med*. 2008;359:1018–26.
40. Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: The Model for End-Stage Liver Disease updated for the modern era. *Gastroenterology*. 2021;161:1887–895.e4.

How to cite this article: Al-Karaghoul M, Ventura-Cots M, Wong YJ, Genesca J, Bosques F, Brown RS, et al. Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design. *Hepatol Commun*. 2024;8:e0495. <https://doi.org/10.1097/HC9.0000000000000495>